Intravenous BU divided four times daily (q6 h) has been shown to be safe and effective in pediatric allo-SCT recipients. Though less frequent dosing is desirable, pharmacokinetic (PK) data on twice daily (q12 h) i.v. BU administration in pediatric allo-SCT recipients is limited. We prospectively examined the PK results in a cohort of pediatric allo-SCT recipients receiving i.v. BU q12 h as part of conditioning before allo-SCT. BU levels were obtained after the first dose of conditioning. PK parameter analysis (n ¼ 49) yielded the following 95% confidence intervals (CI 95 ): weight-normalized volume of distribution: 0.65-0.73 L/kg; t 1/2 : 122-147 min; weightnormalized clearance (CL n ): 3.4-4.3 mL/min/kg; and area under the curve: 1835-2180 mmol Â min/L. From these results, a steady state concentration was calculated with CI 95 between 628-746 ng/mL. Comparison between recipients p4 vs 44 years old revealed significant differences in t 1/2 (mean: 115 vs 146 min, P ¼ 0.008) and CL n (mean: 4.4 vs 3.5 mL/min/kg, P ¼ 0.038). Intravenous BU q12 h had a comparable PK to i.v. BU q6 h PK seen in the literature, and in pediatric allo-SCT recipients, is a feasible, attractive alternative to i.v. q6h dosing.
INTRODUCTION BU, a cytotoxic bifunctional alkylating agent used as part of conditioning regimens in pediatric recipients before allo-SCT, was initially only an oral formulation. 1, 2 The oral formulation's use was limited owing to erratic systemic exposure related to vomiting and unpredictable intestinal absorption. 2 With the introduction of an i.v. formulation in 1999, more consistent BU levels following i.v. administration were anticipated, thereby avoiding subtherapeutic drug levels associated with primary graft failure (PGF) or toxic levels associated with seizures and veno-occlusive disease (VOD). 3, 4 Intravenous BU administered four times daily (q6 h) produces BU levels within the therapeutic range in 60% of pediatric recipients. 5 Body weight and age have both been shown to influence i.v. BU metabolism [6] [7] [8] [9] [10] and this is reflected in q6 h i.v. BU dosing recommendations (1 mg/kg/dose for children p4 years, and 0.8 mg/kg/dose for children 44 years).
Less frequent i.v. BU dosing is desirable, but there are limited published data regarding the safety or pharmacokinetic (PK) of twice daily administration (q12 h) i.v. BU in pediatric allo-SCT recipients. Outcomes with q12 h oral BU in pediatric allo-SCT recipients have been comparable with those in pediatric patients receiving q6 h oral BU dosing 11 and preliminary comparison of q12 h i.v. BU with q6 h i.v. BU performed by our group were encouraging. 12 Additionally, i.v. BU administered q12 h was found to be safe and resulted in therapeutic PK ranges in adult allo-SCT recipients. 13 We herein report the PK and post transplant outcomes of i.v. BU administered q12 h in pediatric recipients during conditioning before allo-SCT.
MATERIALS AND METHODS

Eligibility criteria
We prospectively examined pediatric allo-SCT recipients receiving i.v. BU q12 h at a dose of 3.2 mg/kg/day (4.0 mg/kg/day p4 years old) during conditioning. Only allo-SCT recipients o19 years at the time of BU administration with BU PK data from therapeutic dose monitoring were included in this analysis. The i.v. BU q12 h recipients were enrolled on IRBapproved protocols registered on the clinicaltrials website (http:// clinicaltrials.gov). All patients and/or parents were required to sign an IRB-approved informed consent and assent when applicable. The research was conducted in compliance with the Declaration of Helsinki.
Intravenous BU q12 h administration Pediatric allo-SCT recipients received i.v. BU as part of a conditioning regimen from day À 7 to day À 4 q12 h at a dose of 1.6 mg/kg/dose (2 mg/ kg/dose p4 years). The dose was infused through a central venous catheter over 2 h. All patients received phenytoin (8-10 mg/kg/day) or lorazepam (0.02-0.05 mg/kg, p2 mg q6 h) seizure prophylaxis with BU administration. The q12 h i.v. BU cohort's protocol-driven and diseasespecific conditioning regimens included both myeloablative conditioning and reduced toxicity conditioning (RTC).
Busulfan pharmacokinetics
Blood samples were collected at 60, 120, 180, 300, 360, 420 and 480 min after the start of BU infusion and stored on ice until separation of plasma. PK analysis was performed at the University of Pennsylvania using a validated gas chromatography-mass spectrometry method as originally described by Lai et al. 16 BU PK parameters of volume of distribution (V d ) and elimination constant (k el ) were estimated from the concentration data using a singlecompartment first-order elimination model for i.v. infusion using the WinNonlin, v4.1 in compliance with the company's 'Acceptable Use Policy' (Pharsight Corp., Mountain View, CA, USA). V d was then weight-normalized as a ratio to body weight in kilograms. BU clearance (CL) was calculated using the formula CL Bu ¼ V d Â k el , giving weight-normalized CL (CL n ) as the ratio of CL to body weight in kilograms. The t 1/2 was calculated as Ln(2) over elimination constant. The area under the concentration-time curve from 0 min to infinity (N; AUC) for BU was calculated as the ratio of BU dose and CL. The cumulative daily AUC (AUC/d) was estimated as the number of BU doses per day that is, two times the AUC. The steady state concentration (C ss ) was computed by dividing AUC by the dosing interval (720 min). BU C ss was targeted between 600-900 ng/mL. Follow-up PK of the fifth BU dose was available in select patients who did not achieve target dosing.
GVHD prophylaxis
Acute GVHD (aGVHD) prophylaxis consisted of tacrolimus and mycophenolate mofetil as we have previously described. 17, 18 aGVHD and chronic GVHD (cGVHD) were graded according to Seattle consensus criteria. 19 All patients who engrafted were evaluated for aGVHD. Only patients with sustained engraftment surviving more than 100 days after transplant were evaluated for chronic GVHD.
Supportive care
Growth factors, antibiotic prophylaxis, intravenous immune globulin (IVIG) and transfusion support were as we have previously described. 14, [20] [21] [22] Engraftment and chimerism Neutrophil, platelet, immune cell recovery and PGF were defined as previously described. Donor myeloid and/or lymphoid chimerism was measured on day þ 30, 60, 100, 180 and 365. The percent donor chimerism was determined by quantifying fluorescent-labeled PCR products from donor and recipient alleles at STR loci as previously described. 14, 23 Toxicity and definitions Severe VOD was evaluated according to the McDonald criteria. 24 Toxicity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (http://ctep.cancer.gov/protocoldevelop ment/electronic_applications/docs/ctcaev3.pdf).
Statistics
Individual PK parameter 95% confidence intervals (CI 95 ) were calculated using a t-distribution. Continuous variables were summarized as medians and ranges, mean ± s.e.m., or mean ± half the length of the CI 95 . The impact of baseline clinical characteristics (i.e., conditioning regimen, donor source) on PGF in the q12 h dosing group was described as relative risk, with significance assessed by Fisher's exact test. Continuous variables were compared using the homoscedastic Student's t-test and categorical variables using a two-proportion z-test when comparing subgroups of the q12 h i.v. BU cohort. The impact of first dose BU C ss on BU-associated grade III-IV toxicities was assessed using analysis of variance, and on PGF and aGVHD using Student's t-test. Neutrophil engraftment, platelet engraftment, and aGVHD were assessed using the Kaplan-Meier method. These calculations were performed in Prism 5.03 (GraphPad, La Jolla, CA, USA). In all analyses, a P-value o0.05 was considered significant.
RESULTS
Patient demographics
From April 2003 to October 2010, forty-nine pediatric patients (36 male, 13 female, mean age 7.4 years, range 0.2-18.4 years, mean weight 25.5 kg, range 7-72 kg) were enrolled (Table 1) . Median follow-up for surviving patients in this cohort was 740 days. Patients had a variety of malignant (n ¼ 15) and nonmalignant (n ¼ 34) disease before primary allo-SCT (Table 1) . Although all nonmalignant conditions were classified as stable, malignant disease status varied- Table 1) .
Conditioning regimens and allogeneic donor sources Sixty-five percent of children received RTC regimens including BU/ Flu/Camp (n ¼ 29) and BU/Flu/ATG (n ¼ 3) (Table 1) . Except for patients receiving BU/Cy/ATG/GO, BU was the first conditioning drug administered. Twenty-seven patients received umbilical cord blood transplant (UCBT). Others received either peripheral blood stem cells or BM from matched unrelated donor (MUD) (n ¼ 12) and matched family donor (MFD) (n ¼ 10) (Table 1) .
PK analysis PK data were available on all patients. PK parameters were variable with a greater than threefold interpatient variability in the q12 h i.v. BU recipients. Ninety-five percent CI 95 for PK parameters were as follows: Normalized V d : 0.65-0.73 L/kg; t 1/2 : 122-147 min; CL n : 3.4-4.2 mL/min/kg and AUC: 1845-2186 mmol Â min/L (Table 2, Figure 1a and b). CI 95 for BU exposure as measured by AUC/day and C ss were 3689-4373 mmol Â min/L/day and 631-748 ng/mL, respectively (Table 2, Figure 2a and b). The targeted BU C ss was established in 59% of the patients. Follow-up PK data from the fifth dose of BU were obtained for six patients (three underexposed and three overexposed to BU). The underexposed BU recipients received a mean 38% increase in dose for a mean 64% increase in BU C ss ; the overexposed BU recipients received a mean 48% decrease in BU for Intravenous q12 h BU in pediatric allo-SCT recipients JB Le Gall et al a mean 57% decrease in BU C ss (Tables 3A and B) . Patient PK parameters showed no significant difference between malignant and nonmalignant disease (Table 4) .
PK analysis: age stratified Age stratified (p4 years, 44 years) PK parameters following q12 h i.v. BU administration were assessed (Table 5) . Between age groups, significant differences were seen in t 1/2 and Cl n . CI 95 for t 1/2 : p4 years: 95-136 min; 44 years: 130-162 min; P ¼ 0.008. CI 95 for CL n : p4 years: 3.3-5.3 mL/min/kg; 44 years 3.1-3.9 mL/min/ kg; P ¼ 0.047. Despite differences in t 1/2 and CL n , BU exposure between children p4 years and those 44 years showed no significant differences, P ¼ 0.600. Twelve (67%) patients p4 years and 17 (55%) patients 44 years achieved the targeted BU C ss on first dose (P ¼ 0.416). Intravenous q12 h BU in pediatric allo-SCT recipients JB Le Gall et al PK analysis: infants Infant patients (o1 year) were highlighted for their tremendous variability in i.v. BU PK (Table 6A) . Patients 1 and 3 were overexposed to BU on the first dose (1022 and 1159 ng/mL), whereas another had near half the exposure (665 ng/mL) with the same dose/kg. Dose adjustments and follow-up PK studies were performed on the two infants with high BU exposure (Table 6B) . Both patients showed intrapatient variability in BU CL and exposure, patient 1 demonstrating a 17% increase in CL n and patient 3 having a 18% decrease in normalized V d . Patient 3 (BU C ss : 1159 ng/mL) was the only child to develop severe VOD in the study.
Toxicity
All children were evaluated for toxicities determined to be directly, probably and possibly related to BU exposure. Two children on phenytoin prophylaxis experienced general tonic-clonic seizures with first dose BU C ss of 828 and 770 ng/mL; the average BU C ss of children who developed seizures, 799 ng/mL, was higher than those who did not, 685 ng/mL, but not significantly so (P ¼ 0.401). Six child developed transaminitis (grade III (n ¼ 4), grade IV (n ¼ 2)) and five children developed grade III mucositis. No children developed high-grade hemorrhagic cystitis. One child developed grade III renal failure and another developed grade IV pulmonary toxicity (Table 7) . First dose BU C ss was not significantly associated with the incidence of any of these toxicities.
Hematopoietic reconstitution and donor chimerism Forty-two patients engrafted neutrophils at a median of 21 days (Figure 3a) , 83% of who successfully engrafted platelets at a median of 51 days (Figure 3b ). Of those who engrafted mean whole blood chimerism of 82%, 85%, 89%, 93%, 94% was achieved at days 30, 60, 100, 180 and 365 post transplant, Acute graft-versus host disease The probability of developing grade II-IV aGVHD was 36.7% (CI 95 : 23.3%-50.2%) (grade II: n ¼ 11; grade III: n ¼ 6; grade IV: n ¼ 1) (Figure 4 ). First dose mean BU C ss was 726±49 (s.e.m.) ng/mL in children who developed grade II-IV aGVHD vs 668±31 (SEM) ng/ mL in those who did not (P ¼ 0.302). In the 16-year-old patient who developed grade IV disease, BU C ss was 1217 ng/mL and Cl was 1.8 mL/min/kg. No patients developed extensive chronic GVHD.
DISCUSSION
The study demonstrates that q12 h i.v. BU PK is quite comparable to q6 h i.v. BU PK in pediatric allo-SCT recipients. 10, 12 With the same total daily dose, q12 h i.v. BU recipients have comparable V d , t 1/2 and CL n with q6 h i.v. BU. We have previously described a cohort of q6 h i.v. BU recipients PK, 12 with PK performed at the University of Pennsylvania. The V d , t 1/2 and CL n for that cohort were 20.6 ± 16.6 L, 132.0 ± 31.1 min, 3.6 ± 0.9 mL/min/kg, respectively. 12 As expected, the AUC for a single dose of q12 h BU is approximately double that of q6 h i.v. BU (1077±352 mmol Â min/L). 12 When q12 h and q6 h i.v. BU AUC are converted to C ss , total BU exposure is comparable-q12 h mean C ss : 687 ng/mL vs q6 h mean C ss : 736 ng/mL. 12 In brief, BU exposure is comparable in patients receiving either q12 h or q6 h i.v. BU and the targeted BU C ss is achieved in q12 h i.v. BU at a rate (59%) consistent with previous findings for q6 h i.v. BU. 5 Once daily dosing in pediatric patients has been shown to require a slightly higher dose to achieve similar BU exposure. 25 Kletzel et al. have shown that an i.v. BU test dose (0.8 mg/kg) with subsequent PK analysis can predict the initial daily dose of i.v. BU during conditioning. 26 They successfully target daily AUC via once daily dosing in 24/30 pediatric patients. 26 Still, five young children, half of all children under 2 years, failed to reach target AUC despite a test dose. 26 These results may indicate a shortfall in test dosing and once daily i.v. BU based on intrapatient variability in BU CL in very young children.
We stratified the q12 h i.v. BU patients by age to investigate PK parameters in young patients. Comparing patients p4 years and those 44 years revealed a significant difference in t 1/2 and CL n . Children p4 years demonstrated a 31 min shorter t 1/2 and a 0.9 mL/min/kg faster CL n . The shorter t 1/2 and faster CL n demonstrate the rapidity of BU metabolism in younger patients. The BU exposure in each age group compares well with previously described q6 h results. When q6 h i.v. BU recipients have been dose adjusted to 1 mg/kg p4 years and 0.8 mg/kg for recipients 44 years, mean AUC with s.d. has been reported between 966 ± 170 mmol Â min/L 6 and 1050 ± 266 mmol Â min/L 27 in patients p4 years and 1048±315 mmol Â min/L 10 in patients 44 years. When converted to C ss , p4-year-old patients have an average BU exposure between 660 ± 116 and 718 ± 180 ng/mL. In 44-year-old patients, C ss is 717±215 ng/mL. The mean C ss calculated in this study for patients p4 years old (700 ng/mL) and 44 years old (679 ng/mL) are well within these ranges.
Finally, we specifically examined infant patients o1 year. Tremendous variability was seen in this group of three patients, with 2/3 patients receiving high BU exposure. On follow-up PK of these patients BU exposure decreased with dosing adjustment to the targeted or below the targeted range with near 20% change in some PK parameters. Despite the reduction in BU exposure, one patient developed severe VOD directly related to high BU exposure during the first 2 days (four doses of q12 h i.v. BU).
Advantages of q12 h i.v. BU over q6 h i.v. BU are intuitive: a substantial reduction in human resources required to administer Grade 3 the drug and a theoretical reduction in the risk for central-line infections, due to less frequent accessing of the central line. 28 Compared with once-daily i.v. BU, though, some of these advantages disappear. Data from infant patients may reveal a role for q12 h i.v. BU. With the current method of therapeutic drug monitoring in BU recipients, dosing adjustments are frequently not realized until the third day of drug administration. BU therapeutic drug monitoring labs have the capacity to complete PK data analysis by the end of the second day of drug administration. A q12 h schedule thus allows for dosing adjustments to take effect after the third dose of BU, whereas patients have been exposed to inaccurate BU for 37.5% of the dose. In once-daily BU administration, this change would be impossible until 50% of BU was given inaccurately. Furthermore, as we have shown here a q12 h schedule does not rely on a test dose to determine BU dosing, reducing total BU exposure in recipients.
To assess the safety of q12 h i.v. BU, we analyzed the clinical outcomes of recipients following allo-SCT. Outcomes in VOD and aGVHD were reassuring. Severe VOD (2.0%) and grade II-IV aGVHD (36.7%) in q12 h i.v. BU recipients occurred in an expected range for q6 h i.v. BU recipients. 1 This study has several limitations, including small sample size, and a highly heterogeneous group of primary diseases, conditioning regimens, donor sources, prior treatment and performance status. We did note a high incidence of PGF in q12 h i.v. BU recipients who received unrelated UCBT and RTC. These patients were thirteen times as likely to experience PGF as others in the q12 h cohort. The majority of these patients had nonmalignant conditions. There are likely several factors associated with this high incidence of PGF in chemo-naïve RTC and UCBT recipients, including one log lower TNC/kg and CD34/kg dose, reduced myeloablation, history of blood cell sensitizing transfusions and the presence of marrow failure disorders, among others. First dose q12 h i.v. BU C ss and AUC, however, were not associated with PGF in these patients. Horwitz et al. 29 reported a similar low rate of engraftment (two out of eight patients) in adult UCBT recipients who received BU in RTC regimens. PGF in our study was strongly correlated with donor source and overall conditioning regimen intensity, but we do not believe q12 h i.v. BU dosing significantly increased the risk of PGF. Early protocols involving RTC and UCBT recipients were stopped once data regarding PGF became available.
As discussed q12 h i.v. BU can be an advantageous dosing schedule as compared with q6 h and once-daily schedules. Intravenous BU q12 h is an attractive alternative to q6 h dosing due to the improved utilization of human resources and possible reduction in catheter-associated infections; it may also prove beneficial over daily dosing in patients at risk for not achieving targeted BU exposure. Comparable PK between i.v. BU q12 h and q6 h, as seen in the literature, supports the use of q12 h i.v. BU during conditioning before allo-SCT in pediatric recipients. Furthermore, the low incidences of severe VOD, grade III-IV toxicities, and grade II-IV aGVHD emphasize a strong safety profile. Additional studies in infant patients are needed to determine optimal dosing of i.v. BU in this highly variable cohort. Figure 4 . Cumulative probability by Kaplan-Meier method of grade II-IV acute graft versus host disease in patients following i.v. q12 h BU before allo-SCT in pediatric recipients.
